Hyderabad’s pharmaceutical pollution crisis

The report finds that pharmaceutical production in Hyderabad continues to cause severe environmental degradation through the discharge of untreated wastewater containing heavy metals and industrial solvents. It highlights a critical link between these manufacturing practices and the spread of antimicrobial resistance (AMR), a global health threat. The document argues that Indian regulatory bodies are failing to enforce pollution controls and that the pharmaceutical industry's reliance on opaque supply chains allows companies exporting to the US and EU to avoid accountability for their environmental footprint.

• Water sampling conducted in September 2017 revealed that pharmaceutical factories in Hyderabad are discharging wastewater containing heavy metals and industrial solvents at concentrations "orders of magnitude higher than maximum regulatory limits or safe exposure levels".
• Extremely high levels of hexavalent chromium (CrVI), a known human carcinogen, were detected in multiple samples, indicating a "major risk" to human health and a high potential for accumulation in fish.
• Pharmaceutical pollution in Hyderabad is a significant driver of antimicrobial resistance (AMR); one facility's treated wastewater contained ciprofloxacin at a concentration strong enough to treat 44,000 people.
• Regulatory oversight in India is described as inadequate, with the government reportedly weakening the Comprehensive Environmental Pollution Index (CEPI) and failing to act on data from digital monitoring systems, which were found to be "faulty, incomplete or non-operational".
• The report identifies a pattern of illegal waste dumping, including the use of tankers camouflaged as lorries to release effluent into the Musi River.
• Local communities in Hyderabad suffer severe health issues linked to pollution, including skin and eye conditions, respiratory problems, and reported cases of epilepsy and miscarriages in livestock.
• The proposed 'Hyderabad Pharma City' at Mucherla is facing resistance from local villagers who fear it will simply "turn the land toxic" and shift pollution from one area to another.
• Indian pharmaceutical companies, such as Aurobindo, have significant export links to the US and EU, meaning that pollution in Hyderabad is a global supply chain issue for health providers like the UK's National Health Service (NHS).

APA

Foundation, C. M. (2018). Hyderabad’s pharmaceutical pollution crisis. Changing Markets Foundation. https://changingmarkets.org/wp-content/uploads/2023/10/CM-HYDERABAD-s-PHARMACEUTICAL-POLLUTION-CRISIS-FINAL-WEB-SPREAD.pdf

Chicago

Foundation, Changing Markets. Hyderabad’s pharmaceutical pollution crisis. Changing Markets Foundation, 2018. https://changingmarkets.org/wp-content/uploads/2023/10/CM-HYDERABAD-s-PHARMACEUTICAL-POLLUTION-CRISIS-FINAL-WEB-SPREAD.pdf.

Wikipedia

{{cite report |last1=Foundation |first1=Changing Markets |title=Hyderabad’s pharmaceutical pollution crisis |publisher=Changing Markets Foundation |date=January 2018 |url=https://changingmarkets.org/wp-content/uploads/2023/10/CM-HYDERABAD-s-PHARMACEUTICAL-POLLUTION-CRISIS-FINAL-WEB-SPREAD.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{foundation2018hyderabads, author = {Foundation, Changing Markets}, title = {{Hyderabad’s pharmaceutical pollution crisis}}, institution = {Changing Markets Foundation}, year = {2018}, month = jan, url = {https://changingmarkets.org/wp-content/uploads/2023/10/CM-HYDERABAD-s-PHARMACEUTICAL-POLLUTION-CRISIS-FINAL-WEB-SPREAD.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }